Epigral Reports Strong PAT Growth Amid Rising Borrowing Costs in May 2025 Results

Epigral, a midcap player in the chemicals industry, has released its financial results for the quarter ending March 2025, with the announcement made on May 5, 2025. The company has experienced notable financial performance during this period, although there has been an adjustment in its evaluation, with the score reflecting a shift from 18 to 12 over the last three months.
The financial data indicates that Epigral's Profit After Tax (PAT) for the latest six months stands at Rs 190.52 crore, showcasing a year-on-year growth of 50.79%. This positive trend in PAT suggests a strengthening financial position in the near term. Additionally, the company's operating profit to interest ratio has reached its highest level in the last five quarters at 14.73 times, indicating an enhanced capacity to manage interest obligations.

On the sales front, net sales for the latest six months are reported at Rs 1,272.87 crore, reflecting a year-on-year growth of 27.78%. However, it is important to note that the quarterly interest expense has surged significantly, indicating a rise in borrowing costs.

For more insights on Epigral's financial trends and evaluation changes, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.